Travere Therapeutics (TVTX) EBITDA Margin (2014 - 2026)
Travere Therapeutics (TVTX) reported EBITDA Margin of 29.07% for Q1 2026, up 2231.0% on a YoY basis from 1.25% in Q1 2025, and down 3841.62% quarter-over-quarter from 0.74% in Q4 2025.
Travere Therapeutics (TVTX) EBITDA Margin (2014 - 2026) Analysis & Trends
Travere Therapeutics has reported EBITDA Margin for 13 years, with the latest figure at 29.07% in Q1 2026.
- For the quarter ending Q1 2026, EBITDA Margin rose 2231.0% year-over-year to 29.07%; the trailing twelve-month figure through Mar 2026 stood at 30.88% (up 11337.0% YoY), and the FY2025 full-year result was 286.61%, down 14930.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 29.07%, down from 0.74% in the prior quarter.
- The five-year high for EBITDA Margin was 406.89% in Q3 2023, with the low at 329.91% in Q1 2024.
- Historically, EBITDA Margin has averaged 119.42% across 5 years, with a median of 129.63% in 2024.
- Annual changes were most pronounced in 2023 — EBITDA Margin soared 65007 bps — and 2024, when it tumbled 49305 bps.
- Travere Therapeutics' EBITDA Margin stood at 235.29% in 2022, then climbed by 17 bps to 195.25% in 2023, then jumped by 59 bps to 79.33% in 2024, then jumped by 99 bps to 0.74% in 2025, then plunged by 3842 bps to 29.07% in 2026.
- The last three EBITDA Margin figures came in at 29.07% (Q1 2026), 0.74% (Q4 2025), and 63.66% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Travere Therapeutics | 5.07 Bn | 4.99 Bn | 102.38 Mn | -29.07% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -29.07% |
| Dec 31, 2025 | -0.74% |
| Sep 30, 2025 | 63.66% |
| Jun 30, 2025 | -11.12% |
| Mar 31, 2025 | -51.37% |
| Dec 31, 2024 | -79.33% |
| Sep 30, 2024 | -86.16% |
| Jun 30, 2024 | -129.63% |
| Mar 31, 2024 | -329.91% |
| Dec 31, 2023 | -195.25% |
| Sep 30, 2023 | 406.89% |
| Jun 30, 2023 | -271.18% |
| Mar 31, 2023 | -277.13% |
| Dec 31, 2022 | -235.29% |
| Sep 30, 2022 | -243.17% |
| Jun 30, 2022 | -231.96% |
| Mar 31, 2022 | -329.34% |
| Dec 31, 2021 | 32.61% |
| Sep 30, 2021 | -64.59% |
| Jun 30, 2021 | -72.12% |